Showing 1741-1750 of 3038 results for "".
- Bausch + Lomb and Novaliq Announce Publication of Second Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane)https://modernod.com/news/bausch-lomb-and-novaliq-announce-publication-of-second-pivotal-phase-3-data-on-nov03-perfluorohexyloctane/2481485/Bausch + Lomb and Novaliq announced that the American Journal of Ophthalmology has
- NovaBay Pharmaceuticals Launches Avenova Eye Health Support to Comfort Dry Eyes and Promote Eye Healthhttps://modernod.com/news/novabay-pharmaceuticals-launches-avenova-eye-health-support-to-comfort-dry-eyes-and-promote-eye-health/2481480/NovaBay Pharmaceuticals announced the launch of OTC Avenova Eye Health Support oral supplement featuring a combination of MaquiBright, a nutrient-rich, antioxidant-dense extract of the superfruit maqui berry, and natural triglyceride omega-3 oils, designed to comfort dry eyes and s
- Notal Vision: Clinical Trials Demonstrate Value of Home OCThttps://modernod.com/news/notal-vision-clinical-trials-demonstrate-value-of-home-oct/2481429/Notal Vision reported that the latest data on its investigational home-based optical coherence tomography (OCT) and how the service can be used to manage wet age-related macular degeneration (AMD) were recently presented at the Angiogenesis, Exudation, and Degeneration and Macula Society 202
- Belkin Vision’s New Glaucoma Laser Technology Now Available in Germanyhttps://modernod.com/news/belkin-visions-new-glaucoma-laser-technology-now-available-in-germany/2481425/Belkin Vision announced that its Direct SLT Eagle device, an automated, non-contact glaucoma laser treatment, is being used to treat glaucoma patients at The University Eye Clinic in Bochum, Germany. “The Eagle by Belkin Vision will be transformative for many of the esti
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development/2481420/Novel findings from researchers contradict previous notions about sugar's role in the onset of diabetic cataracts. The team of researchers, led by Prof. Ali Hafezi-Moghadam, MD, PhD, Director of the Molecular Biomarkers Nano-Imaging Laboratory (MBNI) at the Brigham and Wom
- Bruder Healthcare Now Exclusive Licensor of "The Dry Eye Drink"https://modernod.com/news/bruder-healthcare-now-exclusive-licensor-of-the-dry-eye-drink/2481407/Bruder Healthcare, which is part of Hilco Vision, announced an exclusive licensing agreement with Dry Eye Drink LLC, the manufacturer of a portfolio of dry eye products and drink mixes formulated to provide relief for US adults suffering from symptoms of dry eye disease.
- Novaliq Plans to File a Marketing Authorization Application for CyclASol in the EU for Dry Eye Diseasehttps://modernod.com/news/novaliq-plans-to-file-a-markting-authorization-application-for-cyclasol-in-the-eu-for-the-treatment-of-dry-eye-disease-in-july-2023/2481396/Novaliq announced its plans for filing a marketing authorization application (MAA) CyclASol (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED), in the European Union. The Committee for Medicinal Products for H
- FCI Ophthalmics Announces Availability of EzyPor Polyethylene Orbital Implanthttps://modernod.com/news/fci-ophthalmics-announces-availability-of-ezypor-polyethylene-orbital-implant/2481336/FCI Ophthalmics announced the launch of EzyPor in the United States. EzyPor is a high density polyethylene orbital implant with a patented suturing platform, indicated for enucleation, evisceration, and secondary implantation. Ezyor is designed to have a smooth
- Bausch + Lomb and Novaliq Announce Publication of Pivotal Phase 3 Data on NOV03 (Perfluorohexyloctane) in Ophthalmologyhttps://modernod.com/news/bausch-lomb-and-novaliq-announce-publication-of-pivotal-phase-3-data-on-nov03-perfluorohexyloctane-in-ophthalmology/2481330/Bausch + Lomb and Novaliq announced that Ophthalmology has published results from the pivotal phase 3 trial GOBI, which is one of two pivotal phase 3 trials for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) as
- NovaSight Announces Commercial Release of CureSight in the US; Names a New VP of Sales & Marketinghttps://modernod.com/news/novasight-introduces-curesight-to-the-us-and-names-a-new-vp-of-sales-marketing/2481295/NovaSight has announced that its CureSight digital therapy for amblyopia will be released to the US market beginning this month. CureSight received FDA 510(K) clearance based on a pivotal study that found the device to be noninferior to eye patching—t